Home Search

drug development - search results

If you're not happy with the results, please do another search

The Cancer Drug Development Forum

Open Access Government (May 2018) "Thanks for the information. We have already tweeted and shared the article with our contacts. Thanks for this opportunity and feel free to contact me should you have future editions on the topic of cancer."   Marjorie Recorbet, The Cancer Drug Development Forum – CDDF
early drug development

IDEAS: improving design, evaluation and analysis of early drug development studies

Prof Thomas Jaki from the Medical and Pharmaceutical Statistics Research Unit at Lancaster University explores a novel approach to Ph.D. training for those in the pharmaceutical industry
drug development for neurodegenerative diseases concept

Time for a change of tack on drug development for neurodegenerative diseases?

UCB's Duncan McHale outlines why reclassification might be a good idea to boost drug development for neurodegenerative diseases like Alzheimer's and Parkinson's Neurodegenerative diseases are a growing global challenge, as medical advances ensure more individuals live longer. By 2020 there will be more than 40 million people in the world...

The evolution of malaria drug development

David H Peyton at Portland State University outlines how research has discovered that heme is key to malaria drug development

Drug development for neurodegenerative diseases

Professor Duncan McHale, Head Global Exploratory Development at UCB discusses the challenge of developing drugs to treat neurodegenerative diseases

The evolution of malaria drug development

David H Peyton at Portland State University outlines how research has discovered that heme is key to malaria drug development

The pursuit for new strategies in drug development

Prof. Dr. Tanja Gaich, of the University of Konstanz – Department of Chemistry discusses new strategies in drug development and the challenges involved
Paediatric oncology drug development conference 2016

Innovative oncology drug development: Why not children?

SIOPE asks why therapies made available for adults are not extended to children with cancer, and why paediatric oncology drug development is lagging behind Thanks to the increasing introduction of molecular targeting and personalised medicine strategies, innovative medicines and treatments are nowadays available for adults with cancer. Widespread access to...
drug development for neurodegenerative diseases concept

Time for a change of tack on drug development for neurodegenerative diseases?

UCB's Duncan McHale outlines why reclassification might be a good idea to boost drug development for neurodegenerative diseases like Alzheimer's and Parkinson's Neurodegenerative diseases are a growing global challenge, as medical advances ensure more individuals live longer. By 2020 there will be more than 40 million people in the world...

Drug development for cancer and inflammatory disease

Sumith A Kularatne, Vice President of Research and Development at On Target Laboratories shares the research strides he has made in drug development
pills

Reclassifying neurodegenerative diseases for drug development

Professor Duncan McHale, Head Global Exploratory Development, UCB discusses reclassifying neurodegenerative diseases to enable drug development and to help patients... Neurodegenerative diseases are a growing global challenge as medical advances ensures more individuals live longer.  By 2020 there will be more than 40 million individuals in the world with Alzheimer’s disease and...
drug

Drug development for Alzheimer’s disease

Ramón Cacabelos, of EuroEspes Biomedical Research Center discusses the strides being made in drug development for Alzheimer's disease... Alzheimer’s disease (AD) is a major problem of health and a national priority in developed countries. Despite enormous efforts by governments, the scientific community and the pharmaceutical industry over the past 50 years,...

Drug development for Alzheimer’s disease

Alzheimer's disease (AD) is a major problem of health and a national priority in developed countries. Despite enormous efforts by governments, the scientific community and the pharmaceutical industry over the past 50 years, no therapeutic breakthroughs have yet been achieved, and the drugs available for the treatment of AD...

The development of anti-infective drugs

University of Strathclyde’s Professor Colin J Suckling shares research being undertaken into anti-infective and immunomodulatory drug discovery programmes

Development of multiple drug resistance (MDR)

Terra G. Arnason and Troy A.A. Harkness from the Departments of Medicine, and Anatomy and Cell Biology at the University of Saskatchewan detail current strategies to prevent or reverse multiple drug resistant malignancy… Multiple drug resistance (MDR) can be present from the outset (inherent) or develop (acquired) in response to...
The role of chemistry in drug discovery and development

The role of chemistry in drug discovery and development

Sriram Radhakrishnan, Healthcare Analyst at Frost & Sullivan details the vital role chemistry plays in drug discovery and development…   Drug discovery and development is one of the most complex and expensive activities within the framework of the pharmaceutical industry. It encompasses a wide array of end-to-end activities with a plethora...
drug monitoring in cancer

Point-of-care devices for therapeutic drug monitoring in cancer treatment and beyond

DiaChemo is a European project developing a platform technology for point-of-care devices for therapeutic drug monitoring in cancer treatment and beyond, reveals Dr Silke Krol, Head of the Translational Nanotechnology Lab and Coordinator of the DIACHEMO Project.
Duchenne muscular dystrophy

Duchenne muscular dystrophy: A test case for gene-targeted therapy development in rare disease

Laura Hagerty, PhD, Scientific Portfolio Director at the Muscular Dystrophy Association, highlights strategies for gene correction to treat Duchenne muscular dystrophy.
therapeutic drug monitoring

Point-of-care devices technology for therapeutic drug monitoring in cancer treatment and beyond

Christian Siebel and Dott.ssa Bianca Posocco detail the work of DIACHEMO, a Euroepan project developing a platform technology for point-of-care devices for chemotherapeutics and other drugs.
biomakers

Biomarkers and patients’ access to personalised oncology drugs in Europe

Heinz Zwierzina M.D., CDDF Managing Director tells us all about biomarkers and patients’ access to personalised oncology drugs in Europe in this insightful article

Follow Open Access Government